This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: type 2 diabetes

November 2009 Br J Cardiol 2009;16:269-71

CHD risk is being overestimated in diabetes

BJCardio editorial staff

Abstract

In one study, a group led by Dr Andre Pascal Kengne (University of Sydney, Australia), noted that data from the recent ADVANCE (Action in Diabetes and Vascular Disease) trial conducted in more than 7,000 patients with diabetes worldwide, suggested that the UKPDS equation overestimated risk of major coronary heart disease (CHD) by 198%, and the two Framingham equations overestimated the risk by 146% and 289%. A group from Greece led by Dr Athanasios Kofinis (National University of Athens) reported similar findings from a five-year study of more than 900 people with diabetes.

| Full text

July 2009 Br J Cardiol 2009;16:163-6

New NICE guidelines on new treatments for type 2 diabetes

BJCardio editorial staff

Abstract

Summary of therapies and key recommendations are: Insulin therapy (including the long-acting insulin analogues, insulin detemir, insulin glargine) Insulin detemir and insulin glargine, like NPH insulin, provide slowly-released insulin to meet basal requirements.  When the decision to start insulin is made, human NPH insulin should be started; healthcare professionals should consider switching to a long-acting insulin analogue if the patient experiences significant hypoglycaemia, is unable to use the device needed to inject NPH insulin, or needs help to inject the insulin from a carer or healthcare professional, and for whom switching to a lo

| Full text

November 2008 Br J Cardiol 2008;15:301

News from the EASD

Abstract

DIRECT results suggest increased regression of retinopathy in type 2 diabetes Three studies of the effect of candesartan on diabetic retinopathy produced mixed results in the first large-scale programme assessing the effect of an angiotensin receptor blocker on the incidence and progression of eye complications in patients with diabetes. The primary end points in the three DIabetic REtinopathy Candesartan Trials (DIRECT) were just missed. But investigators and independent clinicians argued the data were strong enough to influence clinical practice in secondary care although were insufficient to support a licence change. Professor Anthony Barn

| Full text

January 2007 Br J Cardiol 2007;14:57-60

‘Tidal wave’ of obesity and type 2 diabetes predicted to dominate CVD practice

Jo Waters

Abstract

No content available

| Full text

September 2006 Br J Cardiol 2006;13:347-50

Should cardiologists be interested in albuminuria?

Clive Weston, Achanthodi Vasudev, Daniel Obaid, Saatehi Bandhopadhay, Jiten Vora

Abstract

No content available

| Full text

March 2006 Br J Cardiol 2006;13:113-20

A new therapeutic target: the CB1 receptors of the endocannabinoid system and visceral fat

Colin Waine

Abstract

No content available

| Full text

January 2006 Br J Cardiol 2006;13:66-70

Heart disease prevention – what place for the glitazones?

Michael Kirby

Abstract

No content available

| Full text

March 2004 Br J Cardiol 2004;11:138-43

Will prevention of type 2 diabetes reduce the future burden of cardiovascular disease? The evidence base today

ohn HB Scarpello

Abstract

No content available

| Full text

March 2004 Br J Cardiol 2004;11:129-36

Evolution of the HMG CoA reductase inhibitors (statins) in cardiovascular medicine

Christopher J Packard

Abstract

No content available

| Full text

November 2003 Br J Cardiol 2003;10:462-8

Modified-release nicotinic acid for dyslipidaemia: novel formulation improves tolerability and optimises efficacy

Michael Schachter

Abstract

No content available

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now